254 related articles for article (PubMed ID: 28884605)
1. Nanomedicines: a theranostic approach for hepatocellular carcinoma.
Usmani A; Mishra A; Ahmad M
Artif Cells Nanomed Biotechnol; 2018 Jun; 46(4):680-690. PubMed ID: 28884605
[TBL] [Abstract][Full Text] [Related]
2. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
Varshosaz J; Farzan M
World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
[TBL] [Abstract][Full Text] [Related]
3. Nanomedicine as a putative approach for active targeting of hepatocellular carcinoma.
Elnaggar MH; Abushouk AI; Hassan AHE; Lamloum HM; Benmelouka A; Moatamed SA; Abd-Elmegeed H; Attia S; Samir A; Amr N; Johar D; Zaky S
Semin Cancer Biol; 2021 Feb; 69():91-99. PubMed ID: 31421265
[TBL] [Abstract][Full Text] [Related]
4. Molecular pathogenesis and targeted therapy of hepatocellular carcinoma.
Zender L; Kubicka S
Onkologie; 2008 Oct; 31(10):550-5. PubMed ID: 18854656
[TBL] [Abstract][Full Text] [Related]
5. Current status and future directions of hepatocellular carcinoma-targeted nanoparticles and nanomedicine.
Kumar V; Rahman M; Gahtori P; Al-Abbasi F; Anwar F; Kim HS
Expert Opin Drug Deliv; 2021 Jun; 18(6):673-694. PubMed ID: 33295218
[TBL] [Abstract][Full Text] [Related]
6. Molecular Targets, Pathways, and Therapeutic Implications for Hepatocellular Carcinoma.
Gong J; Chuang J; Cho M; Toomey K; Hendifar A; Li D
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32718047
[TBL] [Abstract][Full Text] [Related]
7. Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma.
Song MJ
World J Gastroenterol; 2015 Apr; 21(13):3843-9. PubMed ID: 25852268
[TBL] [Abstract][Full Text] [Related]
8. Insights into Nanotherapeutic Strategies as an Impending Approach to Liver Cancer Treatment.
Singh A; Shafi S; Upadhyay T; Najmi AK; Kohli K; Pottoo FH
Curr Top Med Chem; 2020; 20(20):1839-1854. PubMed ID: 32579503
[TBL] [Abstract][Full Text] [Related]
9. Upregulated HOXC8 Expression Is Associated with Poor Prognosis and Oxaliplatin Resistance in Hepatocellular Carcinoma.
Xu P; Zhang X; Ni W; Fan H; Xu J; Chen Y; Zhu J; Gu X; Yang L; Ni R; Chen B; Shi W
Dig Dis Sci; 2015 Nov; 60(11):3351-63. PubMed ID: 26123838
[TBL] [Abstract][Full Text] [Related]
10. Drug delivery strategy in hepatocellular carcinoma therapy.
Yang S; Cai C; Wang H; Ma X; Shao A; Sheng J; Yu C
Cell Commun Signal; 2022 Mar; 20(1):26. PubMed ID: 35248060
[TBL] [Abstract][Full Text] [Related]
11. Targeted therapy of hepatocellular cancer.
Wysocki PJ
Expert Opin Investig Drugs; 2010 Feb; 19(2):265-74. PubMed ID: 20074016
[TBL] [Abstract][Full Text] [Related]
12. Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma.
Li M; Zhang W; Wang B; Gao Y; Song Z; Zheng QC
Int J Nanomedicine; 2016; 11():5645-5669. PubMed ID: 27920520
[TBL] [Abstract][Full Text] [Related]
13. New molecular targets for functionalized nanosized drug delivery systems in personalized therapy for hepatocellular carcinoma.
Turato C; Balasso A; Carloni V; Tiribelli C; Mastrotto F; Mazzocca A; Pontisso P
J Control Release; 2017 Dec; 268():184-197. PubMed ID: 29051062
[TBL] [Abstract][Full Text] [Related]
14. Targeting Wnt/β-catenin pathway in hepatocellular carcinoma treatment.
Vilchez V; Turcios L; Marti F; Gedaly R
World J Gastroenterol; 2016 Jan; 22(2):823-32. PubMed ID: 26811628
[TBL] [Abstract][Full Text] [Related]
15. A supramolecular nanoparticle system based on β-cyclodextrin-conjugated poly-l-lysine and hyaluronic acid for co-delivery of gene and chemotherapy agent targeting hepatocellular carcinoma.
Xiong Q; Cui M; Bai Y; Liu Y; Liu D; Song T
Colloids Surf B Biointerfaces; 2017 Jul; 155():93-103. PubMed ID: 28411478
[TBL] [Abstract][Full Text] [Related]
16. Systemic therapies in hepatocellular carcinoma.
Wörns MA; Weinmann A; Schuchmann M; Galle PR
Dig Dis; 2009; 27(2):175-88. PubMed ID: 19546557
[TBL] [Abstract][Full Text] [Related]
17. Magnetic Nanoparticles for Hepatocellular Carcinoma Diagnosis and Therapy.
Ungureanu BS; Teodorescu CM; Săftoiu A
J Gastrointestin Liver Dis; 2016 Sep; 25(3):375-83. PubMed ID: 27689203
[TBL] [Abstract][Full Text] [Related]
18. Drug delivery system targeting advanced hepatocellular carcinoma: Current and future.
Zhang X; Ng HLH; Lu A; Lin C; Zhou L; Lin G; Zhang Y; Yang Z; Zhang H
Nanomedicine; 2016 May; 12(4):853-869. PubMed ID: 26772424
[TBL] [Abstract][Full Text] [Related]
19. c(RGDfK) anchored surface manipulated liposome for tumor-targeted tyrosine kinase inhibitor (TKI) delivery to potentiate liver anticancer activity.
Deepak P; Kumar P; Arya DK; Pandey P; Kumar S; Parida BP; Narayan G; Singh S; Rajinikanth PS
Int J Pharm; 2023 Jul; 642():123160. PubMed ID: 37379892
[TBL] [Abstract][Full Text] [Related]
20. [Hepatocellular carcinoma].
Kondo S; Ueno H; Morizane C; Okusaka T
Gan To Kagaku Ryoho; 2010 Jul; 37(7):1219-23. PubMed ID: 20647702
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
